Precision BioSciences (NASDAQ:DTIL) Stock Price Up 3.6% – What’s Next?

Precision BioSciences, Inc. (NASDAQ:DTIL)’s share price rose 3.6% on Thursday . The company traded as high as $7.17 and last traded at $7.11. Approximately 77,368 shares changed hands during trading, a decline of 2% from the average daily volume of 79,007 shares. The stock had previously closed at $6.86.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a research report on Thursday, August 22nd.

Precision BioSciences Stock Up 2.5 %

The business’s fifty day moving average price is $8.40 and its two-hundred day moving average price is $9.71. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22. The firm has a market capitalization of $55.91 million, a P/E ratio of 121.52 and a beta of 1.71.

Hedge Funds Weigh In On Precision BioSciences

An institutional investor recently bought a new position in Precision BioSciences stock. Janus Henderson Group PLC bought a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned about 8.29% of Precision BioSciences at the end of the most recent reporting period. Institutional investors and hedge funds own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.